# Anne Floquet

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anne-floquet/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,656 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 53 |
| i10-index | 119 |
| OpenAlex ID | https://openalex.org/A5091655083 |
| ORCID iD | https://orcid.org/0000-0002-1078-8554 |
| Works | 498 |

## Researcher papers

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials](https://scholariq.org/papers/neoadjuvant-chemotherapy-versus-debulking-surgery-in-advanced-tubo-ovarian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Uterine Myomas and Treatments](https://scholariq.org/topics/uterine-myomas-and-treatments-2/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.